is...(vegasvic1)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr.Zimmerman from Bayeron AMBS: "I have been involved with Amarantus formally and informally for the past three years supporting the founders as they work tirelessly to advance MANF to a stage where it has real commercial potential," said Robert J. Zimmerman, SD. "While that effort has been centered on Parkinson's disease, I believe additional opportunities exist to diversify this therapeutic candidate. Ischemia/reperfusion, cardiovascular disease, stroke, traumatic brain injury, diabetes and potentially other disease conditions appear to be impacted by MANF based upon preclinical studies and the literature."
TBI (Traumatic Brain Injury) along with the NFL & US GOV'T ...
AMBS & Banyan Biomarkers are the reasons i am in AMBS long.
There are many other reasons but TBI is huge & Banyan & AMBS are the only 2 companies working on a solution. Parkinsons & everything else to me is secondary. Everyone seems to be missing the bigger picture.
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
The real value of AMBS is in TBI ...READ
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
SUNNYVALE, Calif. and ALACHUA, Fla., June 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
SMOKE..EM EXACTLY..tell me how u can increase shareholder value with bad news.HA HA HA jUST BECAUSE PEOPLE CAN TRADE DOES.NT RAZE IQ
MR> P knowing shorty has to cover...look what happened yesterday
the reason we went up when 90% of traders were blocked was because they were covering. The problem is never the shorts but the day traders (IMO). If the shorts never had 2 cover it would be different. Going to CESARS FOR BRUNCH SEE U TONITE.
gOOD LUK WITH SHORTY...THERE LIKE DEALING WITH MENTALLY DEFICIENT_________________....FILL IN THE BLANK.
I have been with AMBS going back to beginning they research isn't like making an ap for ur phone..it takes time..Time has now come.
If anyone thinks that John Commisiog wastd his whole life on a ghost hunt..they hav not done atheir DD.
One last thing ..encourage shortie 2 short it will only makes us more. HO HO HO. C Ya later.
ENGLISH prof. analayed latest 8K on 12-28-12...READ
On 8 November 2012, Amarantus BioScience, Inc. issued a press release indicating that data stemming from its research grant from the Michael J. Fox Foundation would be released to the public in December 2012. The Company has decided to withhold the release of the data until January 8th, 2013 at 1:40pm Pacific time, when the Company’s Chief Scientific Officer Dr. John W. Commissiong will present the data at the OneMedForum 2013 at the Sir Francis Drake Hotel in San Francisco, CA. The presentation will be made available online at. The cause for the delay is the Company is conferring with leading academics and collaborators to confirm various aspects of the data results in order to ensure complete accuracy and transparency. The Company believes confirmation of the results with leaders in the field prior to release to the public is in the best interests of its shareholders.
The studies have uncovered more profound reults than originally expected. The results go beyond what was originally intended that is the reason to have other scientists research further.
Final statement states to (ENSURE) guarantee the results.
Common sense would dictate to ensure shareholder value would not mean devalue the stock...HO HO HO.
If there was bad news they would have put it out. They wouldn't go to a medical conference & embarras themselves. It is obvious that they want the entire medical profession to hear it all at once. Plus the investors & future partners.
This analogy is from a retired NYC detective.
Me thinx that GERALD is alot smarter than evryone thinks. Cusip was timed perfect for a massive run to $1.40.
20 MIL SHARES & 90% CAN'T TRADE WOW ..WAIT TILL MONDAY SHORT DAY.
WILL BE A MONSTER.. EVERYONE IS OFF & HAVE THEIR XMAS BONUSES..
WE MIGHT SEE .25-.35 CENTS ON MONDAY. hOPE THEY KEEP US FROM TRADING ha ha ha
everybody ASK URSELF 1 QUESTION.. R U smarter than the board of directors of AMBS. IF NOT...well the rest is obvious to the longs.
HO HO HO MERRY NEW YEAR..
DR. RUBENFELD doesn't guess.. he knows hell the man invented amoxicillin. That alone should catapult us to the .20's next wekk before studies revealed.
DR. RUBENFELD doesn't guess.. he knows hell the man invented amoxicillin. That alone should catapult us to the .20's next wekk before studies revealed.
Knowing the studies r positive who in their right mind would sell.
Im thinking that Gerald might surprise everyone & put the report out sooner. bye bye shorty.
BYE BYE SHORTIE
Everyone is missing the big picture..59 mil shares traded & we r still @ basically 8 cents. That is 1,760% up from low in Nov. of .004. AMBS is going to trade this way for a long time. That is how the market works. This is gambling at its best. The traders who sold today might have made a good decision or maybe the worst of their life. Either way I luv the action & nothing goes straight up everyday...just unrealistic. Im happy we traded 59 mil today that is the real story here.
ALL THE ORIGINAL BUYERS R BACK IN TOMORROW 4 ANOTHER HUGE RUN.
AMBS IS the 1 place u can make $$$$$ everyday even on bad days if ur good. I kuv it. HO HO HO. Shortie still has to cover..
It only matters if tomorrow is the last day u ever trade...
AMBS is still the same..It is up 1,787% since Nov. @ .004.
If u sell where do u go & what do u buy better than a chance to make bank..problem is only winners win & losers get out early..
a vegas bookie told me along time ago "the reason casinos win is because when people are winning they bet less & shy away...yet
when they are losing they bet more..u have to decide who u are
before the bell tomorrow..weak hands should stay in bed & not be tempted to sell..it is ez 2 do..ho ho ho
AMBS has turned into an ATM machine only THING is u don't have to pay back what u get UNLESSSSS....ur a shortie HA HA HA
GO AMBS ooops sory wrong room
MR P good morning like I said last night if the volume is here we go all day. MJ Fox is the catalyst to the moon. HO HO HO
bye bye shorties.
ALL IN...my prediction 4 today was if we hit 35-mil shares ... .179 & if we hit 50 mil .. .199.
I think even higher today based on volume.
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
PR Newswire
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In life there are things that are bigger than all of us it appears AMBS is that thing. Buy Buy Buy SHORTIES BYE BYE BYE
The interest for ambs is to great to pass up & the float is small plus plus..plus most of us aren't selling. If someone can give me a better place to be I'll listen.
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Govt. is backing TBI & AMBS & Banyan are exclusively working jointly on it. This is just 1 catalyst that is ready to explode the stock into orbit. $ the new guys here. enjoy
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration...
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
Dr. Rubenfeld would not be going to the ONE MED conference to talk about failure..it is so obvious what is going on. Many of you are new here..been here since .004. You newbies fell in a hole but guess what it is lined with gold & diamonds.
33.7 mil shares today ...tomorrow 35-45 mil as high as 50 Mil.
AMBS is a ticket for many to retire. If u got one hold it.
Shorty still has to cover...HO HO HO Merry Xmas.
Dr. Rubenfeld served as a Director of Sarepta Therapeutics, Inc., from 1996. Today SRPT is $25.00 +. Sounds good 2 me. Ho Ho Ho.
Give me MO Mo MO AMBS. That kills ur theory. Do u need more proof..look at amgen he co-founded AMGEN & look where its at today..
Day trading secret...trak stocks low in volume that make big dips between 7-10am vegas time & buy & hold. I track 20 stocks & only daytrade on green days. That is a little of what I do.
never get greedy. in and out.
I traded with a friend who was the #1 trader on wallstreet in the 90's & I learned a lot. But i taught him about penny stocks.
I luv this game. Trade only green days & never hold overnight.
Except the shorties they will need to cover & buy back & take their loses like the trolls they are. Thanx shorty. HO HO HO.
One last thing...Most SMART people would not sell & take big profits @ this time of year for Tax reasons. Why sell & give 35-45% to the tax man. Smart $$$ will roll the dice & play with
the houses $$$$. If u sell u lose both ways.
HO HO HO.
I'm off to the Bellagio to play poker. Talk 2 u guys later.
Mr. P.. ur doing a great job..@ $2.00 we can have a reunion in VEGAS..Should be about 3-4 weeks.
I will predict that on Jan. 9th we go from .245 cents to $1.10...
& 110 mil shares will trade. i'm out GLA except shorty. HO HO HO.
Mr. P if this was the last trade I am ever going to make I would
be fine with it. There is nowhere else to go that has the real potential for a Joint Venture or buyout. & I mean imminent near future.
Even shory will have to find a new home he is being evicted this week.
I say we all chip in an send a limo for Dr. Rubenfeld to get him to the ONE MED conference...Dr. John & Gerald also.
Dr. Rubenfeld served as a Director of Sarepta Therapeutics, Inc., from 1996. Today SRPT is $25.00 +. Sounds good 2 me. Ho Ho Ho.
Give me MO Mo MO AMBS.
Bossboater, then u must know of helen parks..i was there with u.
made a ton there.
Mr. P look at the yearly chart for AMBS & we r still undervalued by .30-.50 cents. The patents alone r woth 250 MIL +.
This is not going up by accident & I also believe the results r known 2 many & that's what is driving this monster.
Dr. Rubenfeld served as a Director of Sarepta Therapeutics, Inc., from 1996. Today SRPT is $25.00 +. Sounds good 2 me. Ho Ho Ho.
Give me MO Mo MO AMBS.
My neurologist knows al about this company from me when I was trading PWRM he knows this company well he's all in & lives in a 7 mil home. He luvs AMBS.